Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new seasonal flu, and a combination seasonal flu/COVID vaccine. Moderna ...

Moderna lost more than 20% of its value on the stock market as the company delivered slashed revenue guidance for 2025, stressing savings as key to its goal of balancing cash flow by 2028.